MedTrace Logo

Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients

NCT03036748 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-12-27

No results posted yet for this study

Summary

The aim of this study is to determine if amiloride, a diuretic drug, is capable of increasing renal salt excretion, lowering blood pressure and inhibiting uPA in kidney transplant recipients with proteinuria compared to normoalbuminuric transplant patients.

Conditions

  • Kidney Transplant; Complications

Interventions

DIETARY_SUPPLEMENT

Standardized sodium diet

Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.

DRUG

Tbl amiloride

Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day

Sponsors & Collaborators

  • Odense University Hospital

    collaborator OTHER

  • Region of Southern Denmark

    collaborator OTHER

  • University of Southern Denmark

    lead OTHER

Principal Investigators

  • Gitte Rye Hinrichs, MD, PHD · Cardiovascular and Renal research

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2021-09-01
Completion
2021-09-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03036748 on ClinicalTrials.gov